ArticleInternational journal of legal medicine2025
Fatalities in opioid agonist treatment with long-acting injectable buprenorphine.
Article in International journal of legal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLong-acting injectable buprenorphine (LAI BUP) is a novel opioid agonist treatment (OAT) medication with several benefits for patients, OAT units, and society. We present a case series of fatalities in OAT with LAI BUP.
methodsThis was an audit of OAT patient records, supplemented with results of post-mortem (PM) investigation. We started with all deaths (N = 604) between 2018 and 2020 in Finland with a buprenorphine or norbuprenorphine finding in PM toxicology and with known substance use history or concomitant findings of illicit drugs. We then examined the patient records of the 43 individuals in OAT at the time of death. We analyzed information on OAT medication, OAT structure, and performance, including concomitant substance use, and PM findings.
resultsTen LAI BUP patients died during the study period, all of them in 2020, out of the 18 patients receiving some OAT that year. Among the LAI BUP patients, four died from buprenorphine poisoning. Eight patients had PM findings of abused drugs, always including unprescribed benzodiazepines. Two patients showed signs of additional buprenorphine use of which their OAT unit was unaware. Three patients were classified as non-compliant with OAT but had received no extra support to tackle their situation. Visits to the OAT clinic had mainly occurred only on injection days.
conclusionsLAI BUP comprised 56% of OAT medication among all deceased OAT patients in 2020. Despite its recognized benefits, LAI BUP treatment was associated with deaths. Psychosocial support among the deceased LAI BUP patients seemed inadequate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.